Research Programs


Lysoclear is a pre-clinical enzyme therapy product under development by Ichor Therapeutics for the treatment of dry age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD). Lysoclear enzymes are engineered to enter the lysosomes of retinal pigmented epithelial (RPE) cells of the macula and eliminate the toxic vitamin A aggregates implicated in disease progression.

Learn More


Ichor Therapeutics has created an assortment of patent pending technologies in the field of oncology, including drug candidates, diagnostic tests, and a high-throughput drug screening platform. The company predominantly focuses on acute myeloid leukemia (AML), a blood cancer with approximately 50,000 new cases per year and a 5-year survival of only 24%.

Learn More


Partners & Friends

Relationships define success.

Our partners, investors, and friends are an extension of our company and the Ichor team. As an organization, we have aligned ourselves with leading corporations, non-profit organizations, government agencies, thought leaders, and generally useful people who share our passion for advancing standard of care for chronic disease.

Blog, Press, News


Accountability • Transparency • Integrity

The Ichor team represents the best of a new breed of researchers who share a commitment to deliver on the promise of medical biotechnology. Guided by the experience of its seasoned pharmaceutical professionals and advisors, our company culture promotes accountability, transparency, and integrity in the design and execution of our programs.

Meet The Team